SCHEMBL5409116

SCHEMBL5409116

Cc1cc(N2CCCCC2)c2c(I)cccc2n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 7/20 0.61
NPY5R Q15761 1/20 0.48
ADRB2 P07550 1/20 0.45
ADRB1 P08588 1/20 0.45
KDM4E B2RXH2 4/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
GAA P10253 2/20 0.40
ACHE P22303 1/20 0.40
MAPK1 P28482 3/20 0.40
HTT P42858 3/20 0.40
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40
CASP1 P29466 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
USP2 O75604 1/20 0.40
LMNA P02545 1/20 0.40
PKM P14618 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CYP1A2 P05177 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5404406 0.99 NCF1 (0.58) NCF1NPY5RADRB2ADRB1KDM4E
SCHEMBL5403902 0.86 NCF1 (0.63) NCF1ADRB2ADRB1KDM4EGAA
SCHEMBL5412099 0.76 NCF1 (0.52) NCF1NPY5RADRB2ADRB1KDM4E
SCHEMBL30511704 0.74 NCF1 (0.97) NCF1NPY5RADRB2ADRB1KDM4E
SCHEMBL5397624 0.74 NCF1 (0.50) NCF1NPY5RADRB2ADRB1KDM4E
SCHEMBL5411141 0.73 KDM4E (0.55) NCF1NPY5RKDM4EL3MBTL1HSD17B10
SCHEMBL5404043 0.72 NCF1 (0.67) NCF1NPY5RADRB2ADRB1KDM4E
SCHEMBL5022719 0.72 NCF1 (0.67) NCF1NPY5RADRB2ADRB1KDM4E
SCHEMBL5412870 0.72 MAPT (0.47) NCF1L3MBTL1LMNACYP1A2MEN1
SCHEMBL5024568 0.71 NCF1 (0.64) NCF1NPY5RADRB2ADRB1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265125-B2 Neuropeptide Y antagonists HOFFMANN-LA ROCHE INC. (US) 2007-09-04 US disclosed
CN-1274676-C Quinoline and quinazoline derivatives HOFFMANN LA ROCHE (CH) 2006-09-13 CN disclosed
US-20050176698-A1 Neuropeptide Y antagonists BREU VOLKER (DE) 2005-08-11 US disclosed
US-6900226-B2 Neuropeptide Y antagonists HOFFMAN-LA ROCHE INC. (US) 2005-05-31 US disclosed
CN-1444563-A Quinoline and quinazoline derivatives HOFFMANN LA ROCHE (CH) 2003-09-24 CN disclosed
EP-1318981-A2 QUINOLINE AND QUINAZOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2003-06-18 EP disclosed
US-20020052356-A1 Neuropeptide Y antagonists F.HOFFMANN-LA ROCHE AG (CH) 2002-05-02 US disclosed
WO-2002020488-A2 QUINOLINE AND QUINAZOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2002-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176698-A1 Neuropeptide Y antagonists NPY5R, NPY4R, NPY2R NCF1 1230/4885NPY5R 1/4885ADRB2 1081/4885
US-20020052356-A1 Neuropeptide Y antagonists NPY5R, NPY4R, NPY2R NCF1 1230/4885NPY5R 1/4885ADRB2 1081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.